 Doxorubicin
"Doxorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
| Descriptor ID |
D004317
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.175 D04.615.562.050.200.175 D09.408.051.059.200.175
|
| Concept/Terms |
Adriblastin- Adriblastin
- Adriblastine
- Adriblastina
- Adriablastine
- Adriablastin
DOXO-cell- DOXO-cell
- DOXO cell
- Urokit Doxo-cell
- Urokit Doxo cell
|
Below are MeSH descriptors whose meaning is more general than "Doxorubicin".
Below are MeSH descriptors whose meaning is more specific than "Doxorubicin".
This graph shows the total number of publications written about "Doxorubicin" by people in this website by year, and whether "Doxorubicin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 0 | 2 | 2 | | 1990 | 0 | 4 | 4 | | 1991 | 2 | 0 | 2 | | 1992 | 2 | 3 | 5 | | 1993 | 1 | 3 | 4 | | 1994 | 0 | 3 | 3 | | 1995 | 1 | 2 | 3 | | 1996 | 1 | 0 | 1 | | 1997 | 3 | 0 | 3 | | 1998 | 3 | 4 | 7 | | 1999 | 2 | 3 | 5 | | 2000 | 2 | 2 | 4 | | 2001 | 2 | 7 | 9 | | 2002 | 1 | 2 | 3 | | 2003 | 2 | 4 | 6 | | 2004 | 4 | 1 | 5 | | 2005 | 0 | 1 | 1 | | 2006 | 2 | 6 | 8 | | 2007 | 2 | 4 | 6 | | 2008 | 0 | 7 | 7 | | 2009 | 3 | 8 | 11 | | 2010 | 1 | 4 | 5 | | 2011 | 2 | 5 | 7 | | 2012 | 1 | 5 | 6 | | 2013 | 3 | 3 | 6 | | 2014 | 2 | 8 | 10 | | 2015 | 1 | 4 | 5 | | 2016 | 4 | 6 | 10 | | 2017 | 1 | 10 | 11 | | 2018 | 0 | 4 | 4 | | 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Doxorubicin" by people in Profiles.
-
Carlson P, Dasgupta A, Grzelak CA, Kim J, Barrett A, Coleman IM, Shor RE, Goddard ET, Dai J, Schweitzer EM, Lim AR, Crist SB, Cheresh DA, Nelson PS, Hansen KC, Ghajar CM. Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy. Nat Cell Biol. 2019 02; 21(2):238-250.
-
He L, Mao C, Brasino M, Harguindey A, Park W, Goodwin AP, Cha JN. TiO2-Capped Gold Nanorods for Plasmon-Enhanced Production of Reactive Oxygen Species and Photothermal Delivery of Chemotherapeutic Agents. ACS Appl Mater Interfaces. 2018 Aug 22; 10(33):27965-27971.
-
Pinnix CC, Ng AK, Dabaja BS, Milgrom SA, Gunther JR, Fuller CD, Smith GL, Abou Yehia Z, Qiao W, Wogan CF, Akhtari M, Mawlawi O, Medeiros LJ, Chuang HH, Martin-Doyle W, Armand P, LaCasce AS, Oki Y, Fanale M, Westin J, Neelapu S, Nastoupil L. Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv. 2018 06 12; 2(11):1334-1343.
-
Stoen E, Kabos P, Borden KC, Brown RJ, Borges VF, Diamond JR. A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer. Oncology (Williston Park). 2018 06; 32(6):298-302.
-
Place AE, Pikman Y, Stevenson KE, Harris MH, Pauly M, Sulis ML, Hijiya N, Gore L, Cooper TM, Loh ML, Roti G, Neuberg DS, Hunt SK, Orloff-Parry S, Stegmaier K, Sallan SE, Silverman LB. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018 07; 65(7):e27062.
-
Wang X, Chen Z, Mishra AK, Silva A, Ren W, Pan Z, Wang JH. Chemotherapy-induced differential cell cycle arrest in B-cell lymphomas affects their sensitivity to Wee1 inhibition. Haematologica. 2018 03; 103(3):466-476.
-
Benasutti H, Wang G, Vu VP, Scheinman R, Groman E, Saba L, Simberg D. Variability of Complement Response toward Preclinical and Clinical Nanocarriers in the General Population. Bioconjug Chem. 2017 11 15; 28(11):2747-2755.
-
Younger ST, Rinn JL. p53 regulates enhancer accessibility and activity in response to DNA damage. Nucleic Acids Res. 2017 Sep 29; 45(17):9889-9900.
-
Major JL, Salih M, Tuana BS. E2F6 protein levels modulate drug induced apoptosis in cardiomyocytes. Cell Signal. 2017 12; 40:230-238.
-
Punia R, Raina K, Agarwal R, Singh RP. Acacetin enhances the therapeutic efficacy of doxorubicin in non-small-cell lung carcinoma cells. PLoS One. 2017; 12(8):e0182870.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|